UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed recurrent ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer
• Measurable disease outside of field of prior radiotherapy OR
• Progressive disease within field after radiotherapy
• Must have had no more than 2 prior chemotherapy regimens
• * At least 1 prior regimen must have included a platinum agent (e.g., carboplatin or cisplatin)
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2 OR
• Karnofsky 60-100%
• Life expectancy
• More than 12 weeks
• Hematopoietic
• WBC at least 3,000/mm\^3
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin no greater than upper limit of normal (ULN)
• AST/ALT no greater than 2.5 times ULN
• Renal
• Creatinine no greater than ULN OR
• Creatinine clearance at least 50 mL/min
• Cardiovascular
• No coronary artery disease
• No symptomatic cardiac dysfunction
• No symptoms suggestive of coronary artery disease with evidence of cardiac pathology
• Pulmonary
• No symptomatic pulmonary dysfunction
• Other
• No prior allergic reaction attributed to compounds of similar chemical or biologic composition to UCN-01 or other agents used in this study
• No insulin-dependent diabetes mellitus
• No other uncontrolled concurrent illness
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 4 weeks since prior biologic therapy
• Chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No prior topotecan (other prior topoisomerase I inhibitors allowed)
• Endocrine therapy
• At least 4 weeks since prior hormonal therapy
• Radiotherapy
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy
• No prior radiotherapy to more than 40% of bone marrow
• No prior mediastinal irradiation
• Surgery
• At least 4 weeks since prior surgery
• Other
• Recovered from all prior therapy
• No other concurrent investigational agents
• No other concurrent anticancer agents or therapies
• No concurrent combination antiretroviral therapy for HIV-positive patients